Moderna begins work on China mRNA manufacturing site
Sign up now: Get insights on Asia's fast-moving developments
The facility in Shanghai would manufacture medicines for the domestic population, said a Moderna spokesperson.
PHOTO: REUTERS
SHANGHAI - United States vaccine maker Moderna began construction of its first facility in China in November to manufacture mRNA medicines, the company said on Nov 28.
Moderna’s Covid-19 vaccine has yet to be approved in China, but the company said in July it had signed a deal with the city government of China’s financial hub Shanghai to work towards opportunities for it to research, develop and manufacture mRNA medicines in the country.
The facility in Shanghai would manufacture medicines for the domestic population, the world’s second largest after India, a spokesperson for Moderna told Reuters.
“Our focus in China is on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China,” it said in an e-mailed statement.
It did not say what it planned to make at the facility and when production might start. REUTERS
